Connect Biopharma, a loss-making clinical-stage biopharmaceutical firm, based in China, has filed for an initial public offering (IPO) to raise up to $100 million on Nasdaq.
Connect, which filed a prospectus with the US Securities and Exchange Commission (SEC) on February 26, is yet to decide on the pricing terms of the IPO. The offering size of $100 million could even be a placeholder subject to change.
